Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

AmeriLife’s ORCA Life Welcomes Advance Planning Partners

AmeriLife

ORCA Life, a leader in the final expense insurance market and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has formally partnered with Advance Planning Partners. Per the agreement, terms of the deal were not disclosed. Advance Planning Partners is a Louisville-based final expense shop with offices in Denver, Houston, Charlotte and Morgantown, W.Va. The firm’s co-owners, Richard Shawn and Michael Huffman, were founding members of ORCA Life in 2016. Now, together with ORCA and alongside its founder and president, Glenn Crabtree, Advance Planning Partners will have expanded access to the best-in-class leadership and resources of ORCA and AmeriLife, including new products and solutions in the Medicare and retirement income space. “Richard and Michael have been a part of the fabric of ORCA Life since the beginning, and today’s announcement is the culmination of our longstanding partnership and belief in what we’ve build together,” said Crabtree. “I couldn’t be more excited to welcome Advance Planning Partners into the fold, and we look forward to helping them continue to grow their company.” Advance Planning Partners will continue to operate under the ORCA banner, while both Shawn and Huffman will remain in their roles as members of ORCA’s executive leadership team. “I’m incredibly proud of what we’ve built at Advance Planning Partners, and am thrilled to make our longstanding connection with ORCA Life official,” said Shawn. “We’ve only scratched the surface of our potential. The sky’s truly the limit as we venture into new territory with more diverse product offerings and the backing of ORCA and AmeriLife.” “This is, indeed, an exciting day, not only for me and Richard, but for our affiliated agents as well,” added Huffman. “This new yet familiar partnership will not only serve to accelerate our company’s growth, but also ensure that our agents are armed with the very best tools, technology and contracts to take their books of business to the next level.” “I’m thrilled to welcome Richard and Michael to the AmeriLife family of companies under Glenn’s and ORCA Life’s continued guidance,” said Scotty Elliott, AmeriLife’s Chief Distribution Officer for Health. “Since partnering with ORCA in 2021, AmeriLife has witnessed firsthand their team’s uncompromising drive to deliver for their clients. The addition of Advance Planning Partners will undoubtedly strengthen both organizations, and we’re excited to further fuel their collective success.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

May 18, 2023 01:00 PM Eastern Daylight Time

Emergent Health Executes Term Sheet and Engagement Letter with Boustead Securities to roll up its Subsidiary, Evolutionary Biologics and other regenerative medicine and products companies

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that it has executed a Term Sheet and Engagement Letter with Boustead Securities to roll up its subsidiary Evolutionary Biologics and other regenerative medicine and regenerative biologic products companies with NO DILUTION to the Emergent Shareholders with a planned $10 million initial capital raise and public offering and application for listing on NASDAQ or NYSE/AMEX. Emergent’s subsidiary, Evolutionary Biologics, and the new brand called Maximus Men’s Health, along with Juventix Regenerative Medical and Interactive Practice Solutions and Nanosthetic. Subsequent to the IPO, Emergent plans to distribute the shares received by Emergent from the sale of Evolutionary Biologics as a dividend to its shareholders, pro rata at NO COST to the Emergent Shareholders. Such a dividend would only occur after Emergent files a Registration Statement with the SEC and it is declared effective. Any potential taxable event resulting from such a dividend would be the responsibility of each individual shareholder, and Emergent advises each shareholder to consult with their professional advisors, and makes no representation as to the taxable or nontaxable event. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. Jim Morrison, former L'Oréal President and Emergent’s full time CEO stated, “Boustead Securities is a world class financial organization. They approached us to participate in rolling up a series of regenerative biologics into a brand-new IPO. When you look at the effect that this transaction, and the previously announced PharmaZu transaction, will have on EMGE, it's amazing. We see this as a great way to maximize valuation for our Company and take EMGE to the next level.” ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website info@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 18, 2023 09:00 AM Eastern Daylight Time

Image

Oxford Cannabinoid Technologies reaches milestone with phase 1 trial approval for pain relief drug

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC Clarissa Sowemimo-Coker tells Proactive's Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, is a significant milestone for the company. Sowemimo-Coker said recruitment for the trial has already begun, with completion expected in the third quarter of 2023. The drug targets chemotherapy-induced peripheral neuropathy (CIPN) and has the potential for other indications like irritable bowel syndrome (IBS) and other neuropathy. The phase 1 trial focuses on safety and will pave the way for phase 2 trials in other indications, she added. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 18, 2023 07:21 AM Eastern Daylight Time

Video

Medinotec creating expansion path for U.S. manufacturing and distribution of niche medical devices

Medinotec Inc

Medinotec CFO Pieter van Niekerk joins Natalie Stoberman from the Proactive studio to discuss how the company's reach in niche medical device manufacturing and distribution is growing in North America. Medinotec is a US-based company with a primary investment in DISA Medinotec, a South African medical device manufacturing and distribution company that is a global leader in tracheal non-occlusive airway dilation technology and medical device design, manufacture and distribution. van Niekerk says the company has taken recent steps to expand in the North American market by obtaining FDA approval for their unique non-occlusive device, as well as listing on the OTCQX market in March of 2023. van Niekerk adds that the company plans to diversify their medical devices through R&D projects, acquisitions, and partnerships, aiming to grow revenue streams and expand their product range. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 17, 2023 11:05 AM Eastern Daylight Time

Video

PathAI Announces IBD Explore, an AI-powered Histopathology Panel to Unlock Insights for Ulcerative Colitis from the Inflammatory Microenvironment

PathAI

PathAI, a global leader in AI-powered pathology, today announced the launch of IBD Explore 1, an artificial intelligence-powered panel of human interpretable features (HIFs) offering unprecedented resolution of the inflammatory microenvironment from H&E whole-slide images. IBD Explore uses more than 600 histopathology features to spatially characterize the inflammatory microenvironment, giving drug developers and clinical researchers the ability to unlock insights to inform the next phase of targeted drug development in ulcerative colitis (UC). According to the Centers for Disease Control (CDC), an increasing number of American adults have faced diagnosis of either UC or Crohn’s disease, known collectively as Inflammatory bowel disease (IBD) over the past two decades. Over the past few decades the global prevalence of UC and Crohn's disease, known collectively as inflammatory bowel disease (IBD) has increased. A Lancet study 2 found that the prevalence increased from 1990 with 79.5 per 100,000 population with IBD to 84.3 per 100,000 population in 2017. Despite this, remission rates for UC drugs have not surpassed 30% 3 and more than 30% of UC patients stop biologic therapy within 12-18 months due to lack or loss of efficacy. 4 These observations underscore the need for biomarkers such as histologic signatures to aid in drug development and patient management. Previous research found histologic measures of response to be a better predictor of drug efficacy for relapse-free survival in UC patients than endoscopy alone. 5 IBD Explore allows researchers enhanced histologic visibility, with the ability to structure and analyze spatial measures on a scalable platform, allowing insights to inform future trials. “IBD Explore provides visibility down to each individual cell in the inflammatory tissue environment and HIFs, and a level of granularity that we’ve never had,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “This level of detail helps researchers identify patient subtypes and develop customized therapeutics with the hopes of greater efficacy and increased remission for UC patients.” In addition to IBD Explore, PathAI also offers automated, AI-powered Geboes scoring with its tool AI Measurement of Histological Index for Ulcerative Colitis, or AIM-HI™UC. Combined, IBD Explore and AIM-HI UC provide IBD drug developers a complete histology solution for translational research and clinical development. “The utilization of AI-powered pathology has the potential to tremendously benefit researchers in drug discovery and clinical development by reducing trial risk and enhancing therapy differentiation,” said Mike Montalto, Ph.D., chief scientific officer at PathAI. “Our suite of AI-powered solutions can reduce the noise in histological-based endpoints for IBD clinical trials and therefore isolate true drug effect. In collaboration with our biopharma partners, we aim to accelerate precision medicine options for millions of patients with UC.” To learn more about IBD Explore, visit www.IBDExplore.com Footnotes 1 IBD Explore is for research use only. Not for use in diagnostic procedures. 2 The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. October 2020. | https://doi.org/10.1016/S2468-1253(19)30333-4 3 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD. The American Journal of Gastroenterology 115():p S7, December 2020. | DOI: 10.14309/01.ajg.0000722904.81509.45 4 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD. The American Journal of Gastroenterology 115():p S7, December 2020. | DOI: 10.14309/01.ajg.0000722904.81509.45 5 Breaking the therapeutic ceiling in drug development in ulcerative colitis. May 2021. | https://doi.org/10.1016/S2468-1253(21)00065-0 About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to be a rapidly expanding organization comprised of innovative thinkers from around the globe, For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

May 17, 2023 10:00 AM Eastern Daylight Time

Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program

Immunic Inc

Immunic Inc president and CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of preclinical data confirming that vidofludimus calcium (IMU-838) acts as a potent nuclear receptor-related 1 (Nurr1) activator, in addition to its known mode of action as a dihydroorotate dehydrogenase (DHODH) inhibitor. Vitt said described it as another exciting milestone for Immunic's lead development program as it suggests that Nurr1 may be responsible for the drug’s postulated neuroprotective effects. The company has also taken steps to strengthen its intellectual property position with the submission of a new patent application in the United States and European Union, he added. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 17, 2023 10:00 AM Eastern Daylight Time

Video

Ergomed in robust shape to keep delivering

Ergomed PLC

Jonathan Curtain, the new CFO of Ergomed, discussed his background and the company's growth prospects in an interview with Proactive London. The specialist services provider to the pharmaceutical industry focuses on growth areas like rare diseases and oncology. Curtain brings extensive experience in finance and investor relations from his previous role as Senior Vice President of Finance at NASDAQ-listed CRO, Icon PLC. With strong financial results in 2022, showing revenue growth of 23% and an increased order book, Curtain expressed confidence in Ergomed's ability to deliver and execute projects, and highlighted their positive outlook for mergers and acquisitions to further strengthen their services. Despite industry headwinds, the company remains optimistic about its future prospects. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 17, 2023 08:59 AM Eastern Daylight Time

Video

Singaporean Telehealth Platform ORA Raises $10 Million Series A to Modernise Healthcare in the Region

ORA

Singaporean telehealth platform ORA has raised a $10 million USD Series A funding. This is the largest telehealth Series A in South-East Asia and was co-led by TNB Aura and Antler with participation from Gobi Partners, Kairous Capital and GMA Ventures, bringing total funding to date above $17 million USD. ORA is the fastest-growing and biggest vertically-integrated telehealth platform in South East Asia delivering over 250,000 consultations and has experienced uninterrupted monthly growth since its 2021 launch. ORA has launched three brands that serve the modern patient living with chronic conditions, making treatment more accessible, convenient and personal. Modules is a first to market online dermatology experience making personalised, prescription skincare accessible with 676 different formulations, andSons offers male health solutions and OVA delivers female reproductive healthcare. Founded by former ZALORA CMO Elias Pour, ORA is uniquely positioned with a diverse, proven leadership team with rich backgrounds across health, tech and consumer brands. Backed by a robust medical advisory board, ORA’s R&D team draws on experience from L’Oréal and Sephora creating high-touch products and experiences that are IP’d and 100% in-house developed. With a strong attention to customer experience, first to market solutions like Modules, andSons and Ova are meeting modern customer expectations head on. These interactions are translating into deeper patient relationships, building retention rates only rivalled by subscription models like Netflix and unrivalled within the industry. 90% of ORA’s patients are first to condition, under 38 years old and have never been treated before. The disconnect between this younger patient population and the traditional healthcare model is ORA’s biggest opportunity. These new patients have a different set of demands such as flexibility and speed which ORA’s telemedicine model is perfectly placed to treat. ORA’s seamless end-to-end experience joins up the fragmented traditional model, linking consultation, education, pharmacy, delivery and post purchase care for unparalleled convenience. “ORA is on a mission to deliver high touch, high-quality care to millions of patients and with our continued growth story throughout SEA, we are thrilled with today's announcement.” said Elias Pour, ORA’s founder and CEO. “ORA has had over 6 million patient touch points provide us with valuable health data through extensive health evaluations and consultation online. This has brought unique insights into these patient’s healthcare expectations that has and will inform future innovations with our key partners.” “We have the high growth potential of DTC, with a very high percentage of healthcare expenditure in our region being out of pocket. This is powered by an underlying SAAS type of recurring revenue, with subscriptions counting for more than 70% of our revenue and our retention is better than Netflix with 10x the monthly order value. We achieved post marketing breakeven at the end of last year on a group level after just 20 months of going live and have a very clear and believable path to profitability that is imminently ahead of us. With this new round of funding ORA will seek to expand its presence into new territories, both geographically and with new offerings. Later this year ORA’s brands will arrive in retail across 1300 tier one stores bringing its accessible, medically-backed range of products to shelves. Looking at different geographies there are opportunities to expand into regions like the GCC. Charles Wong, Founding Partner at TNB Aura commented: “Since ORA’s early days, TNB Aura has been a firm believer and strong supporter of Elias and the ORA team in their unwavering mission to provide access to affordable high-quality healthcare. Their combined focus on specialised, and often taboo, healthcare verticals as well as a direct-to-patient approach has led the team to clearly differentiate itself while delivering market-leading unit economics that meet the tailored needs of patients across the full value chain.” Teddy Himler - Global Partner at Antler added: “Elias and team have learned from the extraordinary rise of telehealth globally and have applied it masterfully to the idiosyncratic (and often challenging) South East Asia region. We are inspired and supportive of their mission to become the “ Healthcare House of Brands” for the ~1B people in South East Asia and GCC who are underserved by the traditional healthcare system. We think ORA’s platform approach is the future of direct-to-patient healthcare globally.” About ORA ORA is a house of healthcare brands powered by a vertically integrated telehealth platform. Founded in 2020 by ex ZALORA CMO Elias Pour, it is now SEA’s fastest growing digital health provider operating in Singapore, Malaysia and the Philippines with additional markets being launched during the rest of 2023. Its growing portfolio of healthcare brands includes Modules (prescription skincare), OVA (women’s health) and andSons (men’s health). Their HQ is located in Singapore. About TNB Aura At TNB Aura, we are investing in and helping to build the future of Southeast Asia. As a thesis-led, high-conviction venture capital firm, we use data-driven methodologies to identify and invest in select companies that are primed for the future and ready to change the very face of their categories. An approved co-investment partner of Enterprise Singapore, we invest US$2-10 million into Series A and B tech startups - and beyond that, we become true partners in their quest to uplift lives of The Next Billion. About Antler Antler is the investor backing the world’s most driven founders from day zero to greatness. Founded on the belief that people innovating is the key to building a better future, we partner with people across six continents to launch and scale high-potential startups that address meaningful opportunities and challenges. Knowing that exceptional founders can come from anywhere with any background, we have offices in 25 cities, including Austin, New York, London, Berlin, Stockholm, Bangalore, Jakarta, Singapore, Seoul, Tokyo, and Sydney. Our global community backs people from the beginning with co-founder matching, deep business model validation, initial capital, expansion support, and follow-on funding. Fueled by a personal passion that goes beyond traditional investing, we have helped create and invested in more than 750 startups across a wide range of industries and technologies, with the goal of backing more than 6,000 by 2030. Contact Details ORA Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.ora.group/

May 17, 2023 07:00 AM Eastern Daylight Time

Image

Instem proves in step with groundbreaking market needs as it posts strong 2022 performance

Instem PLC

Phil Reason, CEO of Instem PLC, joined Proactive with details of the company's 2022 financial performance. The company grew revenues by 28% and underlying earnings were up 32%. It also said it expected to benefit in 2023 from ‘industry consolidation’. Recent success include increased recurring revenue and a renewed contract with the US government's National Toxicology Program. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 17, 2023 03:00 AM Eastern Daylight Time

Video

1 ... 103 104 105 106 107 ... 284